Skip to content

INDEPENDENT EQUITY RESEARCH

  • The Program
  • Reports
  • About Us
  • Contact us
  • The Program
  • Reports
  • About Us
  • Contact us
  • The Program
  • Reports
  • About Us
  • Contact us

INDEPENDENT EQUITY RESEARCH

Read more about the article Safe-T: Private Investment of NIS 22.5M supports positive momentum that is in line with company’s strategy. Target price raised to NIS 9.38

Safe-T: Private Investment of NIS 22.5M supports positive momentum that is in line with company’s strategy. Target price raised to NIS 9.38

  • Post author:jaimeuss_admin
  • Post published:17 בSeptember 2018
  • Post category:Research
  • Post comments:0 Comments

Continue ReadingSafe-T: Private Investment of NIS 22.5M supports positive momentum that is in line with company’s strategy. Target price raised to NIS 9.38
Read more about the article RedHill Biopharma Ltd.: The acceleration of RHB-104 Phase III Study in Crohn’s disease increases company value and share price.

RedHill Biopharma Ltd.: The acceleration of RHB-104 Phase III Study in Crohn’s disease increases company value and share price.

  • Post author:jaimeuss_admin
  • Post published:17 בSeptember 2018
  • Post category:Research
  • Post comments:0 Comments

Continue ReadingRedHill Biopharma Ltd.: The acceleration of RHB-104 Phase III Study in Crohn’s disease increases company value and share price.
Read more about the article DNA Biomedical Solutions Ltd.: The company and its holdings can become a major force in the osteoporosis care market, pending success in next year’s clinical trials.

DNA Biomedical Solutions Ltd.: The company and its holdings can become a major force in the osteoporosis care market, pending success in next year’s clinical trials.

  • Post author:jaimeuss_admin
  • Post published:6 בSeptember 2018
  • Post category:Research
  • Post comments:0 Comments

Continue ReadingDNA Biomedical Solutions Ltd.: The company and its holdings can become a major force in the osteoporosis care market, pending success in next year’s clinical trials.
Read more about the article Vonetize Plc: Investment Opportunity in VOD for Emerging Countries and Israel; Agreement with Triple C is Expected to Significantly Increase Vonetize Revenues

Vonetize Plc: Investment Opportunity in VOD for Emerging Countries and Israel; Agreement with Triple C is Expected to Significantly Increase Vonetize Revenues

  • Post author:jaimeuss_admin
  • Post published:30 בAugust 2018
  • Post category:Research
  • Post comments:0 Comments

Continue ReadingVonetize Plc: Investment Opportunity in VOD for Emerging Countries and Israel; Agreement with Triple C is Expected to Significantly Increase Vonetize Revenues
Read more about the article Safe-T: Private Investment of NIS 22.5M supports positive momentum that is in line with company’s strategy. Target price raised to NIS 9.38

Safe-T: Private Investment of NIS 22.5M supports positive momentum that is in line with company’s strategy. Target price raised to NIS 9.38

  • Post author:jaimeuss_admin
  • Post published:30 בAugust 2018
  • Post category:Research
  • Post comments:0 Comments

Continue ReadingSafe-T: Private Investment of NIS 22.5M supports positive momentum that is in line with company’s strategy. Target price raised to NIS 9.38
INDEPENDENT EQUITY RESEARCH

Tel: +972(0)9.950.2888
Email: equity.research@frost.com

Contact us

Copyright © 2020 Frost & Sullivan. All Rights Reserved.   Privacy Policy.

Accessibility by WAH